Teleflex Stock Earnings Reports

Teleflex reported Q1 2026 continuing-operations results with revenue of $548.3M (+32.3% GAAP; +5.1% pro forma adjusted constant currency) and adjusted EPS of $1.39 (down 3.5% YoY). Management reiterated 2026 guidance: pro forma adjusted constant-currency revenue growth of 4.5%–5.5% and adjusted EPS $6.25–$6.55. Key strategic actions include the July 2025 BIOTRONIK Vascular Intervention acquisition, announced divestitures of acute care, interventional urology and OEM businesses expected to close in H2 2026, and a planned return of proceeds via up to $1B share repurchase and ~$800M debt reduction. Teleflex will begin opportunistic open-market buybacks in Q2 ahead of divestiture closings. The company has launched a multiyear restructuring targeting ~$50M annual pretax savings by mid-2028; first-quarter restructuring work is on track. Q1 margins were pressured (adjusted gross margin 61.4%; adjusted operating margin 18.1%) by tariffs, higher logistics, increased R&D and a supplier-related quality remediation charge tied to two supplier recalls (provisions included in Q1). Management expects the recall remediation to be manageable for the year. They cite ~ $90M of “stranded costs” embedded in 2026 (ratable through the year) but estimate an underlying steady-state adjusted operating margin of ~23% once TSAs/MSAs and divestiture impacts take effect, with meaningful improvement in interest expense and EPS expected in 2027. Leadership changes: Jason Weidman will become CEO effective June 8; Board and governance adjustments announced. R&D focus highlighted on the Freesolve resorbable magnesium scaffold program (BIOMAG-II enrollment ahead of plan; late-2027 readout expected; BIOMAG-III U.S. pivotal to start in 2026).